Presumed Unilateral Acute Idiopathic Maculopathy following H1N1 Vaccination

Jorge, Leonardo Ferreira; Queiroz, Rafael de Pinho; Gasparin, Fabio; Vasconcelos-Santos, Daniel Vítor

doi:10.1080/09273948.2020.1734213

Cited by 19 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, vaccinations against influenza, yellow fever, hepatitis B, and Neisseria meningitidis have been associated with uveitis, acute idiopathic maculopathy, acute macular neuroretinopathy, Vogt-Koyanagi-Harada disease, and multiple evanescent white dot syndrome. 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 …”

Section: Discussionmentioning

confidence: 99%

Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine

Fowler

Martinez

Pallares

et al. 2021

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

Purpose We report the case of a 33-year-old male who presented with unilateral central serous retinopathy three days after the injection of a COVID-19 vaccine. Observations A 33-year-old healthy Hispanic male referred to the ophthalmology service due to blurry vision and metamorphopsia in the right eye without any flashes, floaters, eye redness or pain. The patient reported that 69 hours prior to presentation he received the first dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine. He denied any past ocular history or pertinent medical history. He does not take any medicines and denies stressful factors in his life. The clinical examination and imaging tests were consistent with central serous retinopathy that resolved in three months. Conclusions and importance This is the first report of an ocular complication potentially associated with a COVID-19 vaccination. Our case contributes information of a side effect potentially related to this new vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine

Fowler

Martinez

Pallares

et al. 2021

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

show abstract

“…In this set of patients, ocular manifestation included VKH-like uveitis, choroiditis, iritis, and AIM. AIM was previously reported following coxsackievirus infection and H1N1 vaccination, usually preceded by flu-like symptoms [ 13 ]. As far as we know, this is the first reported inactivated COVID-19 vaccine-related AIM.…”

Section: Discussionmentioning

confidence: 99%

Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen

Chen

et al. 2022

Vaccines

View full text Add to dashboard Cite

Aims: To report potential vaccine-induced ocular adverse events following inactivated COVID-19 vaccination (Sinopharm and Sinovac). Methods: This case series took place at a tertiary referral center in the southeast of China (Xiamen Eye Center in Fujian Province) from February 2021 to July 2021. Patients who received the first dose of inactivated COVID-19 vaccine and developed vaccine-related ocular adverse events within 10 days were included. The diagnosis of vaccine-related ocular adverse events was guided by the World Health Organization causality assessment and the Naranjo criteria. Results: Ten eyes of seven patients (two male individuals) presenting with ocular complaints following COVID-19 vaccine were included in the study. The mean (SD) age was 41.4 (9.3) years (range, 30–55 years). The mean time of ocular adverse event manifestations was 4.9 days (range, 1–10 days). Three patients were diagnosed with Vogt–Koyanagi–Harada (VKH)-like uveitis, one with multifocal choroiditis, one with episcleritis, one with iritis, and one with acute idiopathic maculopathy. Two patients received the second dose of vaccine. One patient had exacerbation of VKH, and one patient had no symptoms. An aqueous humor analysis in three patients revealed elevated proinflammatory cytokines and negative virus copy. All the patients had transient ocular disturbance and responded well to steroids. No recurrence was noted during 6 months of follow-up. Conclusions: Potential ocular adverse events should be reported to increase the awareness of the health community for timely detection and proper treatment.

show abstract

“…A total of 1,572 cases were found. Implicated complications were grouped into six anatomic categories: eyelid and conjunctival conditions (1,122), anterior segment conditions (236), uvea (49), retina (36), optic nerve (118), and orbital (11). Table 5 displays these 6 anatomic categories with basic descriptive features, including mean time between vaccination and alleged complication.…”

Section: Vaersmentioning

confidence: 99%